Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

MYLAN INC
Mes dernières consult.
Most popular
Report
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 08:20pm CET

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.


© PRNewswire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
01/10 Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg
01/08 MYLAN : to Complete $1 Billion Share Repurchase Plan
2017 MYLAN : Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Gen..
2017 MYLAN : Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA,..
2017 WORKDAY : Factory Mutual Insurance Company Decreased Mylan N V (MYL) Stake; Work..
2017 MYLAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
2017 MYLAN TO PRESENT AT GOLDMAN SACHS HE : A View from the Top
2017 Perrigo lines up bid for Merck's consumer health unit - sources
2017 MYLAN : Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Pa..
2017 MYLAN : Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to ..
More news
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close